

WHAT IS CLAIMED IS:

1 1. A method of protecting neuronal cells from the
2 consequences of obesity in a mammal, the method
3 comprising administering to the mammal a neuronal cell
4 protecting amount of an antagonist at the glycine site of
5 the NMDA receptor.

1 2. A method of treating the symptoms and
2 complications of spasticity in a mammal by administering
3 to the mammal a neuronal cell protecting amount of an
4 antagonist at the glycine site of the NMDA receptor.

1 3. A method of treating symptomatic depression in
2 systemic or neurological diseases by administering to a
3 mammal, a neuronal cell protecting amount of an
4 antagonist at the glycine site of the NMDA receptor.

1 4. A method of reducing or preventing neuronal cell
2 injury or death due to ischemia or embolism in post-
3 myocardial infarction patients by administering a
4 neuronal cell protecting amount of an antagonist at the
5 glycine site of the NMDA receptor, to a mammal.

0937866.080099
660230.9982260

1 5. A method of reducing or preventing neuronal cell
2 injury or death due to ischemia or embolism in invasive
3 vascular procedures patients by administering a neuronal
4 cell protecting amount of an antagonist at the glycine
5 site of the NMDA receptor, both pre-procedure and post-
6 procedure for chronic periods, to a mammal.

1 6. A method of reducing or preventing neuronal cell
2 injury or death due to excessive NMDA stimulation in
3 patients with cerebrovascular risk factors by
4 prophylactically administering a neuronal cell protecting
5 amount of an antagonist at the glycine site of the NMDA
6 receptor, to a mammal.

1 7. A method of treating the chronic neurological
2 condition of spasticity by administering a therapeutic
3 amount of antagonist at the glycine site of the NMDA
4 receptor, to a mammal. A

1 8. The method of claim 1, wherein the antagonist is
2 felbamate.